Profound Medical Corp. PROF revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Profound Medical Corp. reported revenue across 2 products and services; the largest, Recurring Non Capital, was $9.73M, 60.4% of the filed sum (+18.1% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Recurring Non Capital$9.73M60.4%+18.1% yoy
- Capital Equipment$6.37M39.6%+161.0% yoy
Members sum to the consolidated $16.1M for this period.
- United States$12.2M76.1%+66.6% yoy
- Canada$3.08M19.1%+26.3% yoy
- Germany$773K4.8%-13.2% yoy
Members sum to the consolidated $16.1M for this period.
- Capital Equipment$2.86M53.6%+249.1% yoy
- Recurring Non Capital$2.47M46.4%+37.4% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.